SCHEMBL2910132

SCHEMBL2910132

O=C(O)C(Cc1ccccc1)C(O)CCCCCOCc1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP3 P08254 5/20 0.47
MMP8 P22894 4/20 0.47
MMP1 P03956 4/20 0.47
MMP9 P14780 3/20 0.45
SLC1A3 P43003 1/20 0.44
SLC1A2 P43004 1/20 0.44
SLC1A1 P43005 1/20 0.44
L3MBTL1 Q9Y468 2/20 0.42
EPHX2 P34913 1/20 0.42
CSNK1E P49674 1/20 0.42
TDP1 Q9NUW8 1/20 0.41
HTT P42858 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
FOLH1 Q04609 1/20 0.40
GBA1 P04062 2/20 0.39
UGCG Q16739 2/20 0.39
GBA2 Q9HCG7 2/20 0.39
CYP1A2 P05177 1/20 0.39
ADRB2 P07550 1/20 0.39
ADRB1 P08588 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2913807 0.87 MMP3 (0.48) MMP3MMP8MMP1MMP9L3MBTL1
SCHEMBL2910314 0.86 CSNK1E (0.48) MMP3MMP8MMP1MMP9CSNK1E
SCHEMBL2915216 0.86 CSNK1E (0.48) MMP3MMP8MMP1MMP9CSNK1E
SCHEMBL8073713 0.81 MMP3 (0.48) MMP3MMP8MMP1MMP9SLC1A1
SCHEMBL15875007 0.80 CSNK1E (0.64) MMP3MMP1SLC1A3SLC1A2SLC1A1
SCHEMBL8609583 0.80 MMP3 (0.53) MMP3MMP8MMP1MMP9SLC1A1
SCHEMBL8879002 0.79 MMP3 (0.49) MMP3MMP8MMP1MMP9SLC1A3
SCHEMBL8722661 0.79 HTT (0.44) MMP3MMP8MMP1MMP9SLC1A3
SCHEMBL2917355 0.78 NPC1 (0.46) MMP3MMP8MMP1MMP9CSNK1E
SCHEMBL2916631 0.78 NPC1 (0.46) MMP3MMP8MMP1MMP9CSNK1E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1751126-B1 ALKYL CARBAMATE-SUBSTITUTED BUTYROLACTONES SERVING AS LIPASE INHIBITORS ABBOTT PRODUCTS GMBH (DE) 2010-09-01 EP disclosed
EP-1751126-A1 ALKYL CARBAMATE-SUBSTITUTED BUTYROLACTONES SERVING AS LIPASE INHIBITORS Solvay Pharmaceuticals GmbH (DE) 2007-02-14 EP disclosed
US-7074822-B2 Alkyl carbamate-substituted β-lactones, process for their preparation, and pharmaceutical compositions containing them SOLVAY PHARMACEUTICALS GMBH (DE) 2006-07-11 US disclosed
US-20050197386-A1 Alkyl carbamate-substituted beta-lactones, process and intermediate products for their preparation, and pharmaceutical compositions containing them SOLVAY PHARMACEUTICALS GMBH (DE) 2005-09-08 US disclosed
WO-2005080366-A1 ALKYL CARBAMATE-SUBSTITUTED BUTYROLACTONES SERVING AS LIPASE INHIBITORS SOLVAY PHARMACEUTICALS GMBH (DE) 2005-09-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197386-A1 Alkyl carbamate-substituted beta-lactones, process and intermediate products for their preparation, and pharmaceutical compositions containing them PNLIP, CEL, LIPE MMP3 2501/4885MMP8 1688/4885MMP1 2155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.